David S. Knopman, Stephen D. Weigand, Heather J. Wiste, Jonathan Graff-Radford, Neill R. Graff-Radford, Ronald C. Petersen, Bradley F. Boeve, Clifford R Jack Jr, Val J. Lowe, Mary M. Machulda, Julie A. Fields, Vijay K. Ramanan, Hugo Botha, Stuart J. McCarter, David T. Jones, Bryan J. Neth, Gregory S. Day, Kejal Kantarci, Alicia Algeciras-Schimnich, Joshua A. Bornhorst, Derek R. Johnson, and the Alzheimer's Disease Neuroimaging Initiative
{"title":"Discrepancies between CSF biomarker and PET determinations of elevated brain amyloid and their prognostic significance","authors":"David S. Knopman, Stephen D. Weigand, Heather J. Wiste, Jonathan Graff-Radford, Neill R. Graff-Radford, Ronald C. Petersen, Bradley F. Boeve, Clifford R Jack Jr, Val J. Lowe, Mary M. Machulda, Julie A. Fields, Vijay K. Ramanan, Hugo Botha, Stuart J. McCarter, David T. Jones, Bryan J. Neth, Gregory S. Day, Kejal Kantarci, Alicia Algeciras-Schimnich, Joshua A. Bornhorst, Derek R. Johnson, and the Alzheimer's Disease Neuroimaging Initiative","doi":"10.1002/alz.70468","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>When cerebrospinal fluid (CSF) and positron emission tomography (PET) measurements for amyloid-beta-peptide (Aβ) related pathology are discordant, therapeutic decision-making becomes uncertain.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>Using data from patients with mild cognitive impairment (<i>n</i> = 541) from the Alzheimer's Disease Neuroimaging Initiative, we examined baseline characteristics and longitudinal clinical outcomes in persons grouped according to normal/abnormal Aβ via concurrent CSF and PET determinations using standard cutpoints.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Discordant groups for brain Aβ status (CSF+/PET− and CSF−/PET+) each represented about 5% of the mild cognitive impairment (MCI) population. Longitudinally, neither discordant group declined more than the CSF−/PET− group on either a memory measure or the Clinical Dementia Rating Sum of Boxes scores over a median 4 years of observation, while the CSF+/PET+ group exhibited worsening on both measures.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>In contrast to the clinical decline observed in the CSF+/PET+ group, persons with MCI and CSF+/PET− or CSF−/PET+ brain amyloid patterns did not exhibit incipient decline.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Discrepant abnormal cerebrospinal fluid (CSF) and positron emission tomography (PET) brain amyloid indicators are uncommon in mild cognitive impairment (MCI).</li>\n \n <li>CSF-PET discrepant persons with MCI tend to have less abnormal values initially.</li>\n \n <li>CSF-PET discrepant persons with MCI have a benign prognosis at 4 years.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 7","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70468","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.70468","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
INTRODUCTION
When cerebrospinal fluid (CSF) and positron emission tomography (PET) measurements for amyloid-beta-peptide (Aβ) related pathology are discordant, therapeutic decision-making becomes uncertain.
METHODS
Using data from patients with mild cognitive impairment (n = 541) from the Alzheimer's Disease Neuroimaging Initiative, we examined baseline characteristics and longitudinal clinical outcomes in persons grouped according to normal/abnormal Aβ via concurrent CSF and PET determinations using standard cutpoints.
RESULTS
Discordant groups for brain Aβ status (CSF+/PET− and CSF−/PET+) each represented about 5% of the mild cognitive impairment (MCI) population. Longitudinally, neither discordant group declined more than the CSF−/PET− group on either a memory measure or the Clinical Dementia Rating Sum of Boxes scores over a median 4 years of observation, while the CSF+/PET+ group exhibited worsening on both measures.
DISCUSSION
In contrast to the clinical decline observed in the CSF+/PET+ group, persons with MCI and CSF+/PET− or CSF−/PET+ brain amyloid patterns did not exhibit incipient decline.
Highlights
Discrepant abnormal cerebrospinal fluid (CSF) and positron emission tomography (PET) brain amyloid indicators are uncommon in mild cognitive impairment (MCI).
CSF-PET discrepant persons with MCI tend to have less abnormal values initially.
CSF-PET discrepant persons with MCI have a benign prognosis at 4 years.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
